|
|
Article: Provectus Pharmaceuticals Gains FDA Clearance of Investigational New Drug Application for Cancer Drug Provecta(TM).
- Article from:
- PR Newswire
- Article date:
- October 11, 2004
CopyrightCOPYRIGHT 2004 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Clinical Trials With Breast Cancer Patients Planned for Early 2005
Provectus Pharmaceuticals, Inc. (BULLETIN BOARD: PVCT) announced today it has achieved FDA clearance of its Investigational New Drug Application (IND) for Provecta(TM) -- a small-molecule, tumor-specific agent designed to treat breast, liver, prostate and other potentially deadly cancers. Provectus announced submission of this application in late August.
Upon initial filing of an IND, the U.S. Food & Drug Administration imposes a thirty-day review period prior to initiation of human clinical studies. This allows the FDA to identify deficiencies in the application that require ...